Abstract. Sporadic, late-onset Alzheimer disease (AD) constitutes the most frequent cause of dementia in the elderly population. AD-related pathology is often accompanied by vascular changes. The predominant vascular lesions in AD are cerebral amyloid angiopathy (CAA) and arteriosclerosis/lipohyalinosis (AS/LH). The present study was carried out to examine the coincidence of these small vessel pathologies during the development of cognitive deficits, amyloid ␤-protein (A␤) deposition, and neurofibrillary tangle (NFT) formation in sporadic late-onset AD. We correlated the clinical dementia rating (CDR) score, the sequential extension of AD-related A␤ deposition into different parts of the brain, and the extension of NFTs to involve more brain regions with the distribution of CAA and AS/LH in 52 human autopsy brains. The extension of CAA and AS/ LH to involve different areas of the brain was associated with a rise of CDR scores and an increase in the extension of A␤ deposition and NFT generation. AD cases showed a higher number of regions with CAA and AS/LH compared to nondemented patients with AD-related pathology and controls. Moreover, we demonstrated a hierarchical sequence in which the different regions of the brain exhibited CAA and AS/LH-affected vessels, allowing the distinction of 3 stages in the development of CAA and AS/LH. The first stage of CAA involved leptomeningeal and neocortical vessels. The second stage was characterized by additional A␤ deposition in allocortical and midbrain vessels. Finally, in a third stage, CAA was observed in the basal ganglia, the thalamus, and in the lower brainstem. In contrast, AS/LH initially affected the basal ganglia in stage A. In stage B this pathology made inroads into the deep white matter, the leptomeningeal arteries of the cortex, the cerebellum, and into the thalamus. Stage C was characterized by AS/LH in brainstem vessels. Our results demonstrate widespread CAA and AS/ LH to be associated with the development of cognitive deficits in AD. A combination of both CAA and AS/LH may, therefore, contribute to neurodegeneration in AD. These data also suggest that small vessel disease due to arteriosclerosis and fibrolipohyalinosis is a potential target for the treatment of AD.
INTRODUCTION
Sporadic late-onset Alzheimer disease (AD) is the most frequent cause of dementia in the elderly population. The extracellular deposition of amyloid ␤-protein (A␤) and the intracellular generation of neurofibrillary tangles (NFTs) represent histopathological hallmarks of AD (1) (2) (3) (4) . Cerebrovascular changes often accompany AD-related pathology (5) (6) (7) (8) (9) (10) . The most common cerebrovascular diseases of small blood vessels in the aged brain include cerebral amyloid angiopathy (CAA) and arteriosclerosis/ lipohyalinosis (AS/LH) (5, 7, (10) (11) (12) . CAA prevails in leptomeningeal and neocortical vessels and less frequently in the cerebellar cortex (9, (13) (14) (15) . On the other hand, AS/LH predominantly occurs in vessels of the striatum, the deep white matter, and of the leptomeninges (10, 11, 16) .
In the aged brain with AD-related pathology, the extension of NFTs (the term extension in the context of this article is defined as the extension of a given pathology to involve more brain regions) and that of A␤ deposits correlate with the degree of dementia (17) (18) (19) (20) (21) and show a hierarchical pattern in the involvement of different brain regions (2, 17, 19, 22) . Although it is well known that AD patients show more severe and widespread CAA compared to nondemented patients (13, 15, 23) , the detailed anatomical distribution of CAA and other microvascular changes in relation to the development of cognitive deficits, NFTs, and A␤ deposits has not been systematically analyzed in the development of AD. It also remains to be studied whether the formation of vascular changes in the AD brain follows a similar anatomical sequence as A␤ deposition (17, 22) or NFT formation (2, 19) .
To identify a role of CAA and AS/LH in AD, we assessed the development of CAA and AS/LH throughout 19 different brain regions in 52 human autopsy brains, including AD cases, nondemented cases with AD-related pathology, and controls without AD-related pathology. Our findings indicate a distinct sequence of CAA and AS/ LH involving different brain regions. Both lesions are associated with the development of dementia in late-onset AD. 
MATERIALS AND METHODS

Clinical Assessment
Fifty-two human autopsy brains of both genders, aged 61 to 97 years, including 17 AD cases, 26 nondemented individuals with AD-related pathology (ADRP) cases, 4 cases without any AD-related pathology (controls), and 5 cases with AD-related pathology and clinical records providing no information about the cognitive status, were investigated (Table 1) . To study all stages in the development of AD, we selected cases from a larger unselected autopsy series using the following criteria: 1) 60 years of age or older, 2) a minimum of 4 cases in each phase of AD-related A␤ pathology (A␤ phases) (17) and controls without AD-related pathology, and 3) inclusion of AD and nondemented cases. The presence or absence of CAA or AS/LH was not used as selection criteria. Familial AD, Down syndrome, Creutzfeldt-Jacob disease, familial CAA, and inflammatory diseases of the brain or the vessels were not included. Also excluded were cases with a history of previous head trauma, large brain tumors, or with vascular malformations. Our goal was to minimize factors that could interfere with vascular A␤ deposition and arteriosclerotic vascular changes, thereby enabling us to study more accurately the effects of degenerative microvascular lesions on the development of sporadic late-onset AD-related A␤ deposits, NFTs, cognitive deficits, as well as on the development of AD in general. Cases with argyrophilic grain disease and AD-related pathology were included in this study (Table 1) .
All patients had been examined 1 to 4 weeks prior to death by different clinicians according to standardized protocols. The protocols included the assessment of cognitive function and recorded the ability to care for and dress self, eating habits, bladder and bowel continence, speech patterns, writing and reading, short-term and long-term memory, and orientation within the hospital setting. These data were used to retrospectively assess the clinical dementia rating (CDR) scores for each patient (24) ( Table 1) . For this purpose, the information from the clinical files was transformed into CDR levels according to the standard CDR-protocol (24) . AD was diagnosed according to recently published consensus criteria (25) . Cases with AD-related NFT and/ or A␤ pathology that were clinically diagnosed as cognitively normal (CDR ϭ 0) were categorized as putative ADRP cases. These cases also include A␤-only and NFT-only cases. The controls showed no dementia (CDR ϭ 0). For cases 48 to 52, clinical recordings did not allow assessment of CDR scores (Table 1) .
Neuropathological Analysis
Tissue was fixed in a 4% aqueous solution of formaldehyde. We excised blocks from the anterior, middle, and posterior medial temporal lobes and embedded them in polyethylene glycol and in paraffin. The polyethylene glycol blocks were microtomed at 100 m and paraffin material at 10 m. We applied this procedure to paraffin sections of the superior frontal gyrus, the superior parietal lobe, Brodmann areas 17, 18 and 19, cingulate gyrus, basal ganglia, basal nucleus of Meynert, septum, hypothalamus, thalamus, midbrain, pons, medulla oblongata, and the cerebellum. Gallyas silver-staining was used to detect AD-related neurofibrillary pathology and the Campbell-Switzer silver method to assess the presence of amyloid plaques (26) .
For topographical orientation and neuropathological diagnosis, we stained paraffin and polyethylene glycol sections with aldehyde fuchsin-Darrow red for lipofuscin pigment and Nissl material or hematoxylin and eosin (H&E). The Prussian blue method was used to detect hemosiderin in macrophages; positive and negative controls were carried out. The Elastica van Gieson staining method was used to identify vascular changes. To verify the degree of AD-related pathology, staging of NFTs according to published criteria (2, 25) (Table 1 ) was performed. Phases of ␤-amyloidosis (A␤ phase) were determined as described recently (17) . The A␤ phases represent the amyloid burden of the brain corresponding to the number of brain regions exhibiting A␤ deposits (17, 22) : 0 ϭ no A␤, 1 ϭ neocortical A␤, 2 ϭ neo-and allocortical A␤, 3 ϭ cortical, diencephalic and striatal A␤, 4 ϭ cortical, diencephalic, striatal and midbrain A␤, 5 ϭ cortical, diencephalic, striatal, midbrain, pontine, and cerebellar A␤.
Assessment of cerebral infarction and intracerebral hemorrhage was performed macroscopically for gross lesions and microscopically for the regions listed by studying H&E-stained sections or aldehyde fuchsin-Darrow red-stained sections. To compare the extension of small vessel changes in cases with and without cerebral infarction, the presence of cerebral infarcts was noted regardless of their age, size, and etiology in a dichotomized manner. It was not differentiated between cases with multiple and single infarcts. To compare the extension of small vessel changes in cases with and without intracerebral hemorrhage, the presence of intracerebral hemorrhage was noted regardless of the age, size, and etiology of the hemorrhage in a dichotomized manner. It was not differentiated between multiple and single hemorrhages. Those cases with intracerebral hemorrhage were further subclassified into cases with clinically relevant hemorrhages and into cases with clinically silent hemorrhages in a dichotomized manner. The diagnosis of clinically relevant intracerebral hemorrhages was restricted to cases with intracerebral hemorrhage as the morphological correlate for neurological deficits. Clinically silent hemorrhages usually represented small hemorrhages in patients without any neurological symptoms.
The presence of atherosclerosis was examined macroscopically in the basal arteries (circle of Willis) and noted in a dichotomized manner. Immunohistochemistry was performed on 10-m paraffin sections from the superior frontal gyrus, superior parietal lobe, Brodmann areas 17, 18 and 19, cingulate gyrus, anterior medial temporal lobe including the entorhinal region, the middle and posterior medial temporal lobe with the hippocampus, basal ganglia, basal nucleus of Meynert, septum, hypothalamus, thalamus, midbrain, pons, medulla oblongata, and the cerebellum. Sections were immunostained after formic acid pretreatment with the following antibodies directed against A␤: A␤ 17-24 (Signet, Dedham, MA: 4G8, 1/5000, 72 h at 4ЊC), and A␤ [1] [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] 
Apolipoprotein E Genotyping
For genotyping of apolipoprotein E (APOE), genomic DNA was extracted either from unfixed frozen brain tissue or from the paraffin-embedded cerebellar cortex. For suitable DNA templates, a one-step polymerase chain reaction (PCR) was used, followed by standard restriction isotyping with the restriction enzyme HhaI (27) . For DNA templates from formaldehydefixed specimens, a semi-nested PCR assay was employed (28) . This method facilitates reliable APOE genotyping of DNA from archival tissue specimens by enhancing the yield of the PCR product. Positive and negative controls were carried out.
Morphological Analysis
Morphological analysis of CAA was based on anti-A␤ 17-24 immunostained sections. It has been shown that the anti-A␤ [17] [18] [19] [20] [21] [22] [23] [24] antibody sufficiently detects all CAA-affected cerebral blood vessels (29) (30) (31) . For the superior frontal gyrus, superior parietal lobe, Brodmann areas 17, 18 and 19, cingulate gyrus, anterior MTL including the entorhinal region, middle and posterior MTL with the hippocampus, basal ganglia, basal nucleus of Meynert, septum, hypothalamus, thalamus, midbrain, pons, medulla oblongata, and the cerebellum, we noted the types of vessels involved in CAA, identified their locations (leptomeninges, cerebral cortex, and white matter), and recorded the number of the above mentioned regions with vessels exhibiting CAA in order to determine the extension of CAA.
Extension of CAA ϭ Number of brain regions exhibiting CAA-affected vessels
Aldehyde fuchsin-Darrow red-, H&E-, and Elastica van Gieson-stained sections were used for the detection of AS/LH changes in vessels. Perivascular lipid-containing macrophages around lipohyalinotic vessels were distinguished from hemorrhage-derived siderophages in Prussian blue-stained sections. The diagnosis of AS/LH encompasses arteriosclerotic, arteriolosclerotic, lipohyalinotic, and fibrohyalinotic changes in small meningeal and parenchymal brain vessels (11) . It was noted whether or not a given region exhibited AS/LH-related lesions regardless of the number and severity of the lesions in this specific area. The same regions studied for the extension of CAA were examined to determine the extension of AS/LH by counting the number of regions in a given brain exhibiting AS/ LH changes.
Extension of AS/LH ϭ Number of brain regions exhibiting AS/LH-affected vessels
To summarize the total area of the brain exhibiting altered small vessels, regardless of the etiology, we determined the extension of both CAA and/or AS/LH by counting the number of regions exhibiting CAA-and/or AS/LH-affected vessels.
Extension of small vessel lesions ϭ Number of brain regions exhibiting CCA-and/or AS/LH-affected vessels
Statistical Analysis
The Spearman correlation analysis for ranked data was employed to study whether the extensions of CAA and of AS/LH were correlated with the A␤ phase, NFT stage, and the CDR score. To identify whether the extension of CAA and AS/LH have an independent effect on the degree of dementia, which is not linked through the correlation of the extension of CAA and AS/LH with that of A␤ deposition and/or NFT generation, a partial correlation analysis was conducted by controlling the influence of A␤ and NFT pathologies.
We used one-way ANOVA to test for differences in the extension of CAA and the extension of AS/LH among controls, ADRP cases, and AD cases on the one hand as well as the A␤ phases, the NFT stages, and CDR scores on the other. In the event of multiple testing, a post-hoc correction was calculated by using the Tamhane T2 post-hoc test. The Kruskal-Wallis H test was used to identify differences among ranked variables such as CDR score, A␤ phases, and NFT stages.
In order to examine the role of cerebrovascular infarction and intracerebral hemorrhage in AD, we tested for differences in the presence of cerebrovascular infarction and intracerebral hemorrhage in non-AD and AD cases, in CAA cases, and non-CAA cases with the Fisher exact test and calculated odds-ratios. An association of cerebrovascular infarcts and intracerebral hemorrhage with the extension of CAA and AS/LH was tested with one-way ANOVA. To compare the occurrence of intracerebral hemorrhages (including both clinically relevant and irrelevant hemorrhages) with the development of clinically relevant intracerebral hemorrhages in cases with and without CAA and with and without AD we calculated the percentages of all cases with hemorrhages as well as those with clinically relevant intracerebral hemorrhages. The Fisher exact test was used to test whether such differences were statistically relevant. The one-way ANOVA was used to identify differences in the extension of CAA and AS/LH between cases with hemorrhages with and without clinical relevance. To determine the effect of the APOE 4-allele frequency on the extension of CAA and AS/LH we used one-way ANOVA corrected for multiple testing by using the Tamhane T2-post-hoc test.
RESULTS
The involvement of vessels from different brain regions in CAA as well as in AS/LH followed distinct sequences. This allowed the distinction of 3 stages of CAA and 3 stages of AS/LH (Figs. 1, 2) . The extension of both vascular pathologies, CAA and AS/LH, was strongly associated with the development of AD (Table 2) .
CAA
The anatomical distribution of CAA-affected vessels allowed the determination of 3 stages of CAA (Figs. 1A,  2A) . In stage 1, CAA was restricted to leptomeningeal and cortical vessels of the neocortex (Fig. 3A, B ) . Stage 2 was characterized by A␤ deposition in vessels of the neocortex, the allocortex (cingulate gyrus, entorhinal cortex, and hippocampus), cerebellum, and the midbrain. In stage 3, CAA-affected vessels were seen in all areas already involved in stage 2 and within the lower brainstem, the basal ganglia, and the thalamus (Fig. 3C) figure) . In stage 3, CAA is also seen in vessels of the basal ganglia, the thalamus, and the basal forebrain. A␤ deposition in the lower brainstem, another feature of CAA stage 3, is not depicted. B: The stages of AS/LH. AS/LH changes are highlighted in blue. First, in stage A, AS/LH changes can be observed in the basal ganglia and in the deep white matter. Stage B is characterized by additional AS/LH in the cortical and cerebellar leptomeninges and in the thalamus. In the final stage of AS/LH (stage C), AS/LH changes expand into vessels of the hypothalamus and the brainstem (cerebellum and brainstem are not shown in this figure). C: A summary of the CAA (red) and AS/LH (blue) pathologies. In controls without AD-related pathology, CAA is absent and AS/LH is restricted to single vessels in the deep white matter or the basal ganglia. In ADRP, CAA affects the occipital, temporal and frontal cortex, and occasionally other neocortical and allocortical areas, whereas AS/LH is restricted to vessels of the basal ganglia, the deep white matter, the thalamus, and the leptomeninges. AD cases exhibit CAA most frequently in all cortical fields, often in the cerebellum and less frequently in the thalamus, the basal ganglia, the basal forebrain, and the lower brainstem. In the AD brain, AS/LH regularly occurs in the basal ganglia, the deep and peripheral white matter, the thalamus, the hypothalamus, the amygdala, and the leptomeningeal vessels. bold arrows) (B) . In AD cases with severe CAA, vascular A␤ deposits also occur in vessels of the basal ganglia (C). AS/LH changes are often absent in controls lacking A␤ deposits and NFTs (D). In cases with AD-related pathology, even if they are nondemented, AS/LH occurs in vessels of the basal ganglia (E-G). These vessels exhibit focal loss of smooth muscle cells, which are replaced by fibrotic material stained in red (arrowheads in E). There is also splitting of the internal elastic lamina. G: Prussian blue negative, lipid-containing macrophages in the perivascular space in a parallel section of (E) stained with the Prussian blue method. The perivascular space around the affected vessel is widened (E). The enlargement of panel (E) depicts that the adjacent brain parenchyma exhibits focal loss of myelin, axons, and oligodendrocytes compared to controls (bold arrows in E, F). Vascular A␤ deposition was accompanied by parenchymal A␤ plaques. In most instances, all regions exhibiting CAA also showed A␤ plaques. In only a few cases was CAA seen in the absence of A␤ plaques in a given area, although A␤ plaques prevailed in other regions. Such anatomical structures showing vascular A␤ deposition in the absence of parenchymal A␤ were the dentate gyrus (22% of cases with vascular A␤ deposits in the dentate gyrus), CA1 (8% of cases with vascular A␤ deposits in CA1), CA4 (37.5% of cases with vascular A␤ deposits in CA4), the cingulate gyrus (9% of cases with vascular A␤ deposits in the cingulate gyrus), the parietal neocortex (5% of cases with vascular A␤ deposits in the parietal neocortex), the pons (33% of cases with vascular A␤ deposits in the pons), and the cerebellum (20% of cases with vascular A␤ deposits in the cerebellum). The other regions studied exhibited CAA only in the presence of A␤ plaques. Two demented and 11 nondemented cases exhibited A␤ plaques in the complete absence of CAA. Both demented cases free of CAA showed the morphological pattern of argyrophilic grain disease in addition to AD-related lesions and, therefore, did not match the diagnosis of pure AD.
The sequences of extension of CAA and A␤ plaques both started in the neocortex and then spread into the allocortex. Afterwards, A␤ plaques occurred in the basal ganglia before the cerebellum was involved (17) . In contrast, the basal ganglia were one of the last regions to develop vascular A␤, while CAA was already present in the cerebellar vessels. Cases exhibiting capillary A␤ deposits indicative for an APOE 4-associated type of CAA (29) were found in all stages of CAA. There was no local association between CAA and NFTs. For example, NFTs were seen in Brodmann area 17 in only 2 NFT stage VI cases whereas 30 brains showed CAA in this region.
AS/LH
The hierarchical involvement of different brain regions with AS/LH vessels allowed the distinction of 3 stages of AS/LH (Fig. 1B) . Stage A was characterized by AS/ LH either in the basal ganglia or in the cerebral deep white matter. Stage B cases exhibited AS/LH changes in the basal ganglia, the deep white matter of the cerebrum and cerebellum, the thalamus, and in the leptomeningeal vessels of the cerebral and cerebellar cortex. Stage C cases showed, in addition to the vascular changes described for stage B, AS/LH changes in the small leptomeningeal and parenchymal vessels of the brainstem and the hypothalamus. Atherosclerosis of large brain vessels such as the vertebral, basilar, anterior, middle and posterior cerebral arteries, and the internal carotid artery was ignored for AS/LH staging.
The severity of AS/LH lesions ranged from splitting of the internal elastic lamina (Fig. 3E, H) , initial fibrotic degeneration, moderate numbers of perivascular lipidcontaining macrophages (Fig. 3G, small arrows) , and slightly enlarged perivascular cavities to a complete loss of smooth muscle cells, fibrosis of the vessel wall (Fig.  3I, J) , aneurysmatic degeneration, fibrohyalinosis of white matter vessels with perivascular loss of myelin, axons, and oligodendrocytes, as well as large perivascular cavities (Fig. 3E, F, large arrows) . A negative Prussian blue staining reaction distinguished lipid-containing macrophages from siderophages (Fig. 3G) . All of these changes were seen in vessels of AD cases as well as of ADRP cases. Splitting of the internal elastic lamina and arteriosclerotic plaques were predominantly observed in small vessels of the leptomeninges (Fig. 3H, I ), whereas fibrohyalinotic and lipohyalinotic changes were found predominantly in vessels of the basal ganglia, white matter, and the thalamus (Fig. 3E-G, J) . AS/LH occurred in the absence of A␤ and NFT pathology in single white matter vessels. With increasing extension of AS/LH, NFTs and A␤ deposits were observed in an increasing number of regions. NFTs and parenchymal A␤ plaques were predominantly seen in the gray matter whereas AS/LH changes were primarily located in large white matter vessels, in vessels of the basal ganglia and the leptomeninges, but not in cortical vessels. Vascular A␤ deposition was predominantly seen in blood vessels not affected by AS/LH. Only few leptomeningeal vessels in cases with severe AS/LH and CAA exhibited both arteriosclerotic changes and A␤ deposition in the vessel wall.
Together, small vessel lesions due to CAA and/or AS/ LH occurred in a mean of 10 different regions in the AD brain (Fig. 4A) . These regions included the entire alloand neocortex, the cerebral white matter, the basal ganglia, and the thalamus (Fig. 1) . Atherosclerotic plaques were seen in the large vessels of the circle of Willis in 25% of the controls, 88% of the ADRP, and 100% of the AD cases.
Statistical Analysis (Fig. 4 ; Table 2 )
Validity of Stages:
The validity of the CAA stages was confirmed by demonstrating that the number of CAAaffected brain regions as represented by the extension of CAA increases with the stage of CAA (Kruskal-Wallis H test: p Ͻ 0.0001). Likewise, the AS/LH stages were validated by a growing number of regions exhibiting AS/ LH changes as represented by the extension of AS/LH (Kruskal-Wallis H test: p Ͻ 0.0001). Since the stages of CAA and AS/LH were ranked variables, we used the interval-scaled extension of CAA and AS/LH for further statistical analysis.
CAA: AD cases showed a higher extension of CAA than ADRP and control cases (one-way ANOVA corrected for multiple testing: p Ͻ 0.05; Fig. 4A ). In control cases, the extension of CAA was lower compared to ADRP and AD cases (one-way ANOVA corrected for multiple testing: p Ͻ 0.05). The extension of CAA correlated with the degree of dementia as determined by the CDR scores (one-way ANOVA: p Ͻ 0.005; Spearman correlation, r ϭ 0.57; Fig. 4B ), the stage of A␤ deposition in the human brain as shown by the A␤ phases (one-way ANOVA: p Ͻ 0.0001; Spearman correlation, r ϭ 0.74; Fig. 4C) , and with the NFT stage (one-way ANOVA; Spearman correlation, r ϭ 0.62; Fig. 4D ). Controlling for A␤ phase and NFT stage, partial correlation between the extension of CAA and the CDR score revealed no significant independent relationship (controlling for A␤: r ϭ 0.17, p ϭ 0.277; controlling for NFT: r ϭ 0.28, p ϭ 0.059), indicating that the correlation between the extension of CAA and the CDR score as seen with the Spearman correlation analysis is linked through A␤ phase and/ or NFT stage. The extension of CAA also correlated with the extension of AS/LH (one-way ANOVA: p Ͻ 0.05; Spearman correlation, r ϭ 0.37). The stages of CAA correlated with the extension of CAA and AS/LH, the NFT stage, and the A␤ phase (Table 2) .
AS/LH: The extension of AS/LH was higher in AD cases compared to ADRP cases and controls (one-way ANOVA corrected for multiple testing: p Ͻ 0.05; Fig.  4A ). ADRP cases showed a higher extension of AS/LH compared to controls without any AD-related pathology (one-way ANOVA corrected for multiple testing: p Ͻ 0.05; Fig. 4A ). The extension of AS/LH increased with the CDR score (one-way ANOVA: p ϭ 0.06; Spearman correlation, r ϭ 0.42; Fig. 4B ), the A␤ phase (one-way ANOVA: p Ͻ 0.005; Spearman correlation, r ϭ 0.51; Fig.  4C) , and with the NFT stage (one-way ANOVA: p Ͻ 0.005; Spearman correlation, r ϭ 0.51; Fig. 4D ). Partial correlation analysis between the extension of AS/LH and the degree of dementia controlled for A␤ phase and NFT stage revealed no independent correlation (controlling for A␤: r ϭ 0.06, p ϭ 0.67; controlling for NFT: r ϭ 0.13, p ϭ 0.393). In so doing, the correlation between the extension of AS/LH and the CDR score as seen in the Spearman correlation analysis is linked through A␤ phase and/or NFT stage. The extension of AS/LH increased up to and including NFT stage V and decreased slightly in NFT stage VI (Fig. 4D) . The stages of AS/LH correlated with the NFT stage and the phase of ␤-amyloidosis (Table  2) .
Total Small Vessel Lesions due to CAA and AS/LH:
The number of brain regions with small vessel pathology regardless of their etiology was summarized as extension of small vessel lesions and this parameter was higher in AD cases than in ADRP and controls (one-way ANOVA corrected for multiple testing: p Ͻ 0.005; Fig. 4A ; Table  2 ). The extension of small vessel lesions also correlated with the CDR score (one-way ANOVA: p Ͻ 0.005; Spearman correlation, r ϭ 0.56; Fig. 4B; Table 2 ), the A␤ phase (one-way ANOVA: p Ͻ 0,0001; Spearman correlation, r ϭ 0.74; Fig. 4C ; Table 2 ), and with the NFT stage (one-way ANOVA: p Ͻ 0.0001; Spearman correlation, r ϭ 0.69; Fig. 4D ; Table 2 ). Partial correlation analysis controlled for A␤ phase and NFT stage revealed no independent correlation between the extension of small vessel lesions and the CDR score (partial correlation controlling for A␤ phase: r ϭ 0.127, p ϭ 0.401; controlling for NFT stage: r ϭ 0.229, p ϭ 0.126), indicating that the correlation between the extension of small vessel lesions and the CDR score as seen in the Spearman correlation analysis is one through A␤ phase and/or NFT stage. A relationship was also noted for CAA stage and AS/LH stage and the extension of small vessel lesions (Table 2) .
APOE: The extension of CAA was higher in carriers of the APOE 4-allele than in non-carriers (one-way AN-OVA corrected for multiple testing: p Ͻ 0.05). Carriers of an APOE 4-allele showed a slightly greater extension of AS/LH than non-APOE 4 carriers but this trend failed to reach significance (one-way ANOVA corrected for multiple testing: p ϭ 0.085). The extension of small vessel lesions was higher in carriers of the APOE 4-allele compared to non-carriers (one-way ANOVA corrected for multiple testing: p Ͻ 0.05).
Infarction: Cerebral infarction was found in 70.6% of the AD cases but in only 35.5% of the ADRP and control cases (odds ratio: 4.1, confidence interval: 1.152-14.923; Fisher exact test: p Ͻ 0.05). 48.5% of the cases with CAA and 42.1% of cases without CAA showed cerebral infarction (Fisher exact test: p ϭ 0.5455). The extension of CAA was higher in cases with cerebral infarction than in those without (one-way ANOVA: p Ͻ 0.05; Table 2 ). Cases with cerebral infarction also exhibited a slightly greater extension of AS/LH than cases without cerebral infarction (one-way ANOVA: p ϭ 0.1) and a significantly greater extension of small vessel lesions due to CAA and AS/LH (one-way ANOVA: p Ͻ 0.05).
Intracerebral Hemorrhage: Intracerebral hemorrhagic lesions at both the macroscopical and microscopical level occurred in 17.7% of AD and in 29.0% of ADRP and controls (Fisher exact test: p ϭ 0.4923), whereas large clinically relevant intracerebral hemorrhages were seen in 11.8% of the AD but only in 7.7% of the nondemented cases (Fisher exact test: p ϭ 1).
Intracerebral hemorrhage was detected histopathologically in 18.2% of cases with CAA and in 36.8% of the cases without CAA (Fisher exact test: p ϭ 0.1866), whereas hemorrhages with clinical relevance occurred in 9.1% of the CAA cases and in 10.5% of cases without CAA (Fisher exact test: p ϭ 1). This indicates that 50% of the hemorrhages occurring in CAA cases became clinically relevant compared to 29% of the hemorrhages in non-CAA cases. The extension of CAA did not show an effect on the prevalence of clinically relevant hemorrhage in comparison to silent hemorrhages (one-way ANOVA: p ϭ 0.524). The extension of AS/LH did not differ between cases with and without intracerebral hemorrhage (ANOVA: p ϭ 0.39; Table 2 ). Although the extension of AS/LH was slightly higher in cases with clinically relevant intracerebral hemorrhages than in those with clinically silent hemorrhages, this parameter failed to reach significance (one-way ANOVA: p Ͻ 0.284).
DISCUSSION
In this study we show that the extension of CAA and AS/LH is increased in AD cases. Although it is wellknown that AS/LH lesions occur in the presence as well as in the absence of AD (5, 11, 16) , our data indicate that widespread small vessel lesions due to both CAA and AS/LH may play a critical role in the development of AD. This hypothesis is supported by our finding of a strong correlation between the extension of small vessel lesions with the CDR score as well as with both histopathological hallmarks of AD, NFTs, and A␤ deposits. The relationship between the extension of CAA and AS/ LH and the degree of dementia is presumably not an independent one. Partial correlation analysis suggests that these vascular changes occur in concert with AD-related A␤ deposition and NFT pathology. Thus, small vessel changes due to CAA and AS/LH appear to be an integral component of AD-related pathology. The fact that nondemented ADRP cases with early stages of NFT and A␤ pathology show a higher extension of small vessel lesions compared to controls free of A␤ and NFTs is also compatible with an involvement of small vessel changes in the pathogenesis of AD. Hence, our results confirm an association between AD and CAA (7-9, 23, 32) as well as AS/LH (5, 7, 10, 16) . The findings presented here extend the present knowledge of AD-related vascular pathology insofar as we show that the extension of small vessel changes throughout the entire brain is associated with the development of AD-related A␤ and NFT pathology and with the development of cognitive deficits (Fig. 4) . Our results suggest that small vessel changes represent an important histopathological component of AD and may contribute to neurodegeneration in late-onset AD.
To further characterize the role of small vessel lesions for the deposition of A␤ and for the generation of NFTs, we analyzed the anatomical distribution of CAA and AS/ LH and its relation to parenchymal A␤ deposition and NFT generation. Our results show that CAA and AS/LH develop in the different brain areas in a distinct hierarchical sequence that can be described by 3 stages for CAA and AS/LH (Fig. 4) . The development of CAA starts in stage 1 in leptomeningeal and cortical vessels of the occipital, parietal, temporal and frontal neocortex, expands in stage 2 into allocortical and cerebellar regions, and finally involves the basal ganglia, the white matter, the thalamus, and the lower brainstem in stage 3. On the other hand, AS/LH commences in the basal ganglia and the deep white matter (11, 33) (stage A), expands into the vasculature of the cortical leptomeninges, the thalamus, and the cerebellum (stage B), and finally affects small leptomeningeal and parenchymal brainstem vessels (stage C). Both the stages of CAA and those of AS/LH correlated with the NFT stages and A␤ phases and were higher in AD cases than in ADRP and controls.
Initial A␤ deposits in the cortical vessels occur in parallel with the onset of parenchymal A␤ deposition in this area (17) . Subsequently, vascular A␤ pathology expands into vessels of the allocortex and the cerebellum before vascular A␤ deposits occur in the thalamus and the basal ganglia. This sequence is different from that seen for parenchymal A␤ plaques. Here, the thalamus and the basal ganglia exhibit A␤ deposits before A␤ plaques occur in the cerebellum (17) . Despite these differences in the sequences of vascular and parenchymal A␤ deposition, vascular A␤-changes were strongly associated with the parallel development of A␤ plaques in the same region, indicating a close local relationship between parenchymal and vascular A␤ deposition. The late involvement of thalamic and basal ganglia vessels in comparison to the development of A␤ plaques in this region may point to a lower susceptibility for vascular A␤ deposition in these areas as compared to the surrounding brain parenchyma. Several mechanisms may account for a reduced susceptibility for CAA: 1) Perivascular spaces in the basal ganglia differ in their anatomy from those in the cortex (34) . 2) Branches of the middle cerebral artery in the basal ganglia and the thalamus that contain central channels of the periarterial pathways for interstitial fluid drainage (35) (36) (37) accumulate extracellular A␤ only in the event that the periarterial channels in the distal branches of these arteries are already filled with A␤ deposits. 3) Preexisting AS/LH changes of these vessels may reduce the interstitial fluid drainage via periarterial pathways resulting in deposition of A␤ in distal parts of the periarterial pathways. The third explanation is supported by our finding that AS/LH changes occur early in the development of AD within the major branches of the middle cerebral artery, for example, in the basal ganglia and in the deep white matter. Initial AS/LH of central brain arteries can also be discussed as a possible mechanism for initial parenchymal A␤ deposition as a consequence of impaired A␤ clearance from the brain parenchyma along periarterial channels (38) . The local pattern of CAA is different from that of NFT generation and may not be directly linked.
The stages of AS/LH show that these small vessel changes also occur in a sequence in which vessels of distinct brain regions are involved. It appears that proximal arteries in the basal ganglia and in the deep white matter are particularly susceptible to AS/LH whereas smaller distal arteries, such as cortical arteries, less frequently exhibit AS/LH pathology. The hierarchical involvement of distinct brain regions in small vessel lesions due to arteriosclerosis, arteriolosclerosis, fibrohyalinosis, and lipohyalinosis argues in favor of summarizing these vascular changes as AS/LH.
In our sample, cerebral infarction was more frequently found in AD cases as compared to ADRP and controls. Since only a marginal significance was noted concerning the association between AD and cerebral infarction, a separate study in a larger series of cases appears warranted. A recent report supports an association between cerebral infarction and AD (39) . On the other hand, 29.4% of our AD cases did not show any cerebral infarction. Since we show that AD brains without cerebral infarction also contain a significant amount of small vessel changes, one may conclude that small vessel lesions play a pathogenetic role in AD independent of cerebral infarction. Impaired perfusion of the affected microvasculature leads to alterations in the cerebral blood flow with hypoperfusion of the brain parenchyma as shown in magnetic resonance imaging and single photon emission computed tomography studies in AD patients (40) (41) (42) (43) (44) and in animal experiments (45, 46) . Although there is no local relationship between AS/LH and the generation of NFTs, it is tempting to speculate that cortical hypoperfusion due to AS/LH in the central branches of the middle cerebral artery induces hypoxia and leads to -protein dephosphorylation and translocation of this protein into the perikaryon (47) while hypoperfusion-induced excitotoxicity supports abnormal phosphorylation of theprotein (48) . Such a scenario may represent a possible link between vascular changes and -protein function and phosphorylation status.
CAA and AS/LH may support the development of larger hemorrhages that become clinically relevant. Arguments favoring this view are 1) Intracerebral hemorrhage occurs in cases with and without CAA and 2) hemorrhages become more frequently clinically relevant in CAA cases, although in our sample small clinically silent hemorrhages were more frequently seen in CAA cases. Since our results fail to reach significance, further studies are required to clarify the mechanisms of CAA-and/or AS/LH-induced intracerebral hemorrhage.
Current consensus criteria recommend the diagnosis of AD in cases with NFT stages V and VI and a high score of neuritic plaques. Cases with NFT stages III and IV and moderate numbers of neuritic plaques allow the diagnosis of AD in the event that other causes for dementia can be excluded (25) . A diagnosis of vascular dementia is recommended in patients with cerebral infarction and vessel lesions due to AS/LH, atherosclerosis, and other vascular disorders in the absence of significant AD-related pathology (49) . Cases with an overlapping pattern of vascular and AD lesions are often categorized as mixed dementia or as AD with cerebrovascular disease (5, 49) . Our finding that an increased extension of small vessel lesions in the brain is a regular histopathological feature of sporadic late-onset AD in contrast to ADRP and controls raises an obvious problem in the differential diagnosis between vascular dementia, AD, and mixed dementia. The detection of abnormalities in cerebral perfusion and of cerebral infarction is not suited to distinguish AD from vascular dementia (39, 41, 42) . This notion is supported by a recent study indicating that small cerebral infarcts do not increase the level of dementia in AD (50), whereas larger infarcts may alter cognitive function (51) , as well as infarcts in patients with low levels of ADrelated pathology (52) . Therefore, our data together with those of other authors favor the hypothesis that small cerebral infarcts in late-onset AD cases can be interpreted as a complication of AD-related small vessel lesions rather than as evidence for non-AD-related vascular events.
Our results suggest that AS/LH in the brain may serve as a potential target for the treatment of AD. This target also argues in favor of using statins in late-onset AD patients not only for their A␤-lowering effects (53, 54) .
